Evidence map›Paper›PMID 41446201›Full record

ArticlebioRxiv : the preprint server for biology2025

Human MutLα activates methylpurine DNA glycosylase to induce alkylation damage cytotoxicity.

Mohamed E Ashour, Ellissa Krekeler, Monika Chandan Bhowmik, Ning Tsao, Carlos Herrera-Montávez, Miaw-Sheue Tsai, Holland Kantar, Manal Zaher, Roberto Galletto, Nima Mosammaparast

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Mohamed E AshourDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ellissa KrekelerDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Monika Chandan BhowmikDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ning TsaoDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Carlos Herrera-MontávezDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Miaw-Sheue TsaiBiological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Holland KantarDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Manal ZaherDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Roberto GallettoDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Nima MosammaparastDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-5453-5914

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI WALTER J. CHAZIN · 2001 to 2026
$89.6M
Functions of DNA helicases at hard-to-replicate sites and telomere regulationR35GM139508 · NIGMS · WASHINGTON UNIVERSITY · PI GALLETTO, ROBERTO · 2021 to 2025
$2.2M
An RNA-Dependent Innate Immune Response Pathway to Base-Damaging ChemotherapeuticsR01CA282733 · NCI · WASHINGTON UNIVERSITY · PI Nima Mosammaparast · 2024 to 2026
$1.5M
RNA damage induced DNA breaks: A new mechanism of genome instabilityR01GM160854 · NIGMS · WASHINGTON UNIVERSITY · PI MOSAMMAPARAST, NIMA · 2025 to 2025
$855k
NCI NIH HHS P01 CA092584NCI NIH HHS R01 CA282733NIGMS NIH HHS R01 GM160854NIGMS NIH HHS R35 GM139508
6 · The paper itself

Abstract

Alkylation chemotherapy is commonly used against tumors such as glioblastoma, yet resistance often develops through downregulation of mismatch repair (MMR). Previous work has established that loss of MMR prevents the excision of the thymine-containing strand across

Identifiers

PMID41446201
PMCPMC12724163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.